Clinically approved immunomodulators ameliorate behavioral changes in a mouse model of hereditary spastic paraplegia type 11.

"Conflict of interest JB was employed by EVerZOM. SP was employed by TSE systems. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision."

"The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Federal Ministry of Education and Research (BMBF) [TreatHSP.net, Project 9, 01GM1905F (RM und JG)], and the Elite Network of Bavaria “Translational Neuroscience” (to RM)."